Compare MDV & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | MIST |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.6M | 163.2M |
| IPO Year | 2022 | N/A |
| Metric | MDV | MIST |
|---|---|---|
| Price | $14.56 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 30.1K | ★ 3.4M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | ★ 8.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,479,000.00 | N/A |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $0.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.62 | $0.63 |
| 52 Week High | $17.15 | $2.77 |
| Indicator | MDV | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 70.83 |
| Support Level | $14.50 | $2.52 |
| Resistance Level | $14.83 | $2.75 |
| Average True Range (ATR) | 0.33 | 0.19 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 58.86 | 86.54 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).